Prevention of Hepatocellular Carcinoma

ABSTRACT

Prevention is the only realistic approach for reducing mortality rates associated with hepatocellular carcinoma (HCC) worldwide. Vaccination against hepatitis B and screening of blood donations are effective measures of primary prevention. Screening of blood donations has led to a substantial reduction in viral hepatitis transmission among the general population, and in Taiwan vaccination against hepatitis B caused a significant reduction in HCC incidence among infants. Primary prevention also includes approaches that alter epigenetic and genetic changes in hepatocytes, known to increase susceptibility to HCC, as well as treatments slowing progression to cirrhosis. The only evidence that chemoprevention reduces HCC risk is a multicenter randomized prospective study in Asian patients with advanced hepatitis B who received the oral nucleoside analogue lamivudine. Circumstantial evidence suggests that HCC risk is also reduced in patients with chronic hepatitis C who have had a sustained virological response to interferon therapy. HCC is not substantially reduced in patients with hepatitis B treated with interferon and patients with hepatitis C who did not respond to interferon. Secondary prevention, that is, prevention of tumor recurrence after hepatic resection or local ablative therapies, has been pursued with different approaches. Retinoids, hepatic embolization with ¹³¹I lipiodol, and adoptive adjuvant immunotherapy have yielded encouraging results. Other approaches, including those based on interferon alfa or β, provided inconclusive evidence for secondary prophylaxis of HCC, mainly because of the poor methodologies and scientific background of the studies. Dietary interventions and antiaflatoxin agents might help to prevent HCC in susceptible individuals, but the real efficacy of these approaches is far from being demonstrated.

KEYWORDS

Hepatocellular carcinoma - hepatitis C - hepatitis B - interferon - hepatitis B vaccine

REFERENCES

• 1 Bosch F X, Ribes J, Diaz M, Cléries R. Primary liver cancer: worldwide incidence and trends.  Gastroenterology. 2004;  127 S5-S16
• 2 Yu M C, Yuan J M. Environmental factors and risk for hepatocellular carcinoma.  Gastroenterology. 2004;  127 S72-S78
• 3 Bralet M P, Regimbeau J M, Pineau P et al.. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases.  Hepatology. 2000;  32 200-204
• 4 Schreiber G B, Busch M P, Kleinman S H, Korelitz J J. for the Retrovirus Epidemiology Donor Study . The risk of transfusion-transmitted viral infection.  N Engl J Med. 1996;  334 1685-1690
• 5 Mele A, Spada E, Sagliocca L et al.. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy.  J Hepatol. 2001;  35 284-289
• 6 Chang M H, Chen C J, Lai M S et al.. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.  N Engl J Med. 1997;  336 1855-1859
• 7 Jenkins C NH, Buu C, Berger W, Son D T. Liver carcinoma prevention among Asian Pacific Islanders. Getting hepatitis B shots into arms.  Cancer. 2001;  91 252-256
• 8 Ascherio A, Zhang S M, Hernan M A et al.. Hepatitis B vaccination and the risk of multiple sclerosis.  N Engl J Med. 2001;  344 327-332
• 9 Goh J, Callagy G, McEntee G et al.. Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis: three case reports and review of the literature.  Eur J Gastroenterol Hepatol. 1999;  11 915-919
• 10 Global Alliance for Vaccines and Immunization (GAVI) .Report of the Second Board Meeting, Davos, Switzerland, 31 January 2000; GAVI/00.01, available at www.who.int
• 11 Busch M P. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients.  Transfus Clin Biol. 2001;  8 200-206
• 12 Kapusta J, Modelska A, Figlerowicz M et al.. A plant-derived edible vaccine against hepatitis B virus.  FASEB J. 1999;  13 1796-1799
• 13 Wogan G N. Aflatoxin as a human carcinogen.  Hepatology. 1999;  30 573-575
• 14 Wild C P, Hall A J. Primary prevention of hepatocellular carcinoma in developing countries.  Mutat Res. 2000;  462 381-393
• 15 Wang J S, Shen X, He X et al.. Protective alterations in phase 1 and 2 metabolism of aflatoxin B₁ by oltipraz in residents of Qidong, People’s Republic of China.  J Natl Cancer Inst. 1999;  91 347-354
• 16 Egner P A, Wang J B, Zhu Y R et al.. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer.  Proc Natl Acad Sci USA. 2001;  98 14601-14606
• 17 Tang L, Tang M, Luo H et al.. Chemoprevention trial of green tea polyphenol in high-risk population of liver cancer: modulation of serum and urinary aflatoxin biomarkers.  Cancer Epidemiol Biomarkers Prev. 2003;  12 1349S , (abst)
• 18 La Vecchia C, Negri E, Cavalieri D’Oro L, Franceschi S. Liver cirrhosis and the risk of primary liver cancer.  Eur J Cancer Prev. 1998;  7 315-320
• 19 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors.  Gastroenterology. 2004;  127 S35-S50
• 20 Morgan M Y. Alcoholic liver disease: natural history, diagnosis, clinical features, evaluation, management, prognosis and prevention. In: Bircher J, Benhamou JP, McIntyre N, et al Oxford Textbook of Clinical Hepatology. 2nd ed. Oxford; Oxford University Press 1999: 1185-1238
• 21 Papatheodoridis G V, Manesis E, Hadziyannis S J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.  J Hepatol. 2001;  34 306-313
• 22 Lampertico P, Del Ninno E, Viganò M et al.. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.  Hepatology. 2003;  37 756-763
• 23 Craxì A, Di Bona D, Cammà C. Interferon-α for HBeAg-positive chronic hepatitis B.  J Hepatol. 2003;  39 S99-S105
• 24 Liaw Y F, Sung J JY, Chow W C et al.. Lamivudine for patients with chronic hepatitis B and advanced liver disease.  N Engl J Med. 2004;  351 1521-1531
• 25 Di Marco V, Marzano A, Lampertico P et al.. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.  Hepatology. 2004;  40 883-891
• 26 Yoshida H, Shiratori Y, Moriyama M et al.. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance programs of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan.  Ann Intern Med. 1999;  131 174-181
• 27 Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.  J Hepatol. 2001;  34 593-602
• 28 Papatheodoridis G V, Papadimitropoulos V, Hadzyiannis S J. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis.  Aliment Pharmacol Ther. 2001;  15 689-698
• 29 Arase Y, Ikeda K, Marushima N et al.. The long-term efficacy of glycyrrhizin in chronic hepatitis C patients.  Cancer. 1997;  79 1494-1500
• 30 Habu D, Shiomi S, Tamori A et al.. Role of vitamin K₂ in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver.  JAMA. 2004;  292 358-361
• 31 Gelatti U, Covolo L, Franceschini M et al.. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study.  J Hepatol. 2005;  42 528-534
• 32 Kumada T, Nakano S, Takeda I et al.. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma.  Hepatology. 1997;  25 87-92
• 33 Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma.  N Engl J Med. 1999;  340 1046-1047
• 34 Muto Y, Moriwaki H, Ninomiya M et al.. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma.  N Engl J Med. 1996;  334 1561-1567
• 35 Takayama T, Sekine T, Makuuchi M et al.. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.  Lancet. 2000;  356 802-807
• 36 Lau W Y, Leunt T WT, Ho S KW et al.. Adjuvant intra-arterial lipiodol-iodine-131 for resectable hepatocellular carcinoma: a prospective randomised trial.  Lancet. 1999;  353 797-801
• 37 Boucher E, Corbinais S, Rolland Y et al.. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma.  Hepatology. 2003;  38 1237-1241
• 38 Oon C J, Chen W N. Lymphoblastoid alpha-interferon in the prevention of hepatocellular carcinoma (HCC) in high-risk HBsAg-positive resected cirrhotic HCC cases: a 14-year follow-up.  Cancer Invest. 2003;  21 394-399
• 39 Lin S M, Lin C J, Hsu C W et al.. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors.  Cancer. 2003;  100 376-382
• 40 Shiratori Y, Shiina S, Taretani T et al.. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.  Ann Intern Med. 2003;  138 299-306
• 41 Ikeda K, Arase Y, Saitoh S et al.. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-a prospective randomized study of hepatitis C virus-related liver cancer.  Hepatology. 2000;  32 228-232